Avid Bioservices (CDMO) Misses Q2 EPS by 2c, Revenue Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Avid Bioservices (CDMO) Misses Q2 EPS by 2c, Revenue Beats

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments

September 6, 2022 4:05 PM EDT

-- Recorded First Quarter Revenue of $36.7 Million --

-- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $157 Million --

-- Facilities and Capabilities Expansions in Mammalian and Cell and Gene Therapy Businesses Continue on Schedule --

TUSTIN, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to... More